<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Dendreon</title>
	<atom:link href="http://www.psa-rising.com/blog/tag/dendreon/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Wed, 25 Nov 2009 18:36:49 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Provenge Trial Ongoing &amp; Recruiting At Eight US Centers</title>
		<link>http://www.psa-rising.com/blog/2009/11/provenge-open-label-trial/</link>
		<comments>http://www.psa-rising.com/blog/2009/11/provenge-open-label-trial/#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:18:45 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[Sipuleucel-T]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2269</guid>
		<description><![CDATA[An open-label study of Sipuleucel-T (Provenge) is ongoing at 8 centers across the USA. This is a Phase 2 Study enrolling men with  Metastatic Castrate Resistant Prostate Cancer (CRPC). 
The aim of this study is to measure the immune responses to treatment with sipuleucel-T (Provenge).  All participants will receive the drug. 
&#8220;Subjects will [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/11/provenge-open-label-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dendreon to seek Provenge approval in November &#8211; Reuters</title>
		<link>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/</link>
		<comments>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/#comments</comments>
		<pubDate>Thu, 24 Sep 2009 14:57:22 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2017</guid>
		<description><![CDATA[Reuters and WAll Street Journal report today that Dendreon plans to seek US FDA approval for Provenge prostate cancer vaccine in November. Dendreon  &#8220;expects regulators to act on the application by the middle of next year, the company said on Thursday.&#8221;
To start from an updated report in the Wall Street Journal, which adds this [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prostate Cancer Doctor Receives Death Threat Over Provenge</title>
		<link>http://www.psa-rising.com/blog/2007/06/prostate-cancer-doctor-receives-death-threat-over-provenge/</link>
		<comments>http://www.psa-rising.com/blog/2007/06/prostate-cancer-doctor-receives-death-threat-over-provenge/#comments</comments>
		<pubDate>Mon, 04 Jun 2007 04:25:39 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/06/03/prostate-cancer-doctor-receives-death-threat-over-provenge</guid>
		<description><![CDATA[Oncologist Dr. Howard I. Scher has received a death threat for opposing immediate FDA approval of Dendreon&#8217;s Provenge therapeutic vaccine for prostate cancer.  Another oncologist who opposes approval of Provenge without completion of an ongoing clinical trial, Dr. Maha Hussain, has received unspecified threats.

The background to these threats goes back to March 29, when [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/06/prostate-cancer-doctor-receives-death-threat-over-provenge/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
		</item>
		<item>
		<title>ABC-TV Provenge Story Expected to Air Monday June 4</title>
		<link>http://www.psa-rising.com/blog/2007/06/abc-tv-provenge-story-expected-to-air-monday-june-4/</link>
		<comments>http://www.psa-rising.com/blog/2007/06/abc-tv-provenge-story-expected-to-air-monday-june-4/#comments</comments>
		<pubDate>Sat, 02 Jun 2007 23:10:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[RaiseAVoice]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/06/02/abc-tv-provenge-story-expected-to-air-monday-june-4</guid>
		<description><![CDATA[Jan Manarite of Raise a Voice Campaign writes:
Prostate cancer patients have been watching for the prostate cancer/Provenge story on ABC World News with Charles Gibson.  I just got a call from Dr Moyad that ABC called the prostate cancer patient who was interviewed for that story, and informed him that it would air Monday [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/06/abc-tv-provenge-story-expected-to-air-monday-june-4/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dendreon Says FDA Will Accept Either Interim or Final Analysis</title>
		<link>http://www.psa-rising.com/blog/2007/05/dendreon-says-fda-will-accept-positive-interim-data/</link>
		<comments>http://www.psa-rising.com/blog/2007/05/dendreon-says-fda-will-accept-positive-interim-data/#comments</comments>
		<pubDate>Thu, 31 May 2007 16:27:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/05/31/dendreon-says-fda-will-accept-positive-interim-data</guid>
		<description><![CDATA[Dendreon  announced today that the FDA will accept &#8220;either a positive interim or final analysis of survival&#8221; from its ongoing Phase III randomized clinical trial of Provenge immunotherapy for androgen independent prostate cancer.
In a press release, the company said it &#8220;has received confirmation that the U.S. Food and Drug Administration (FDA) will accept either [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/05/dendreon-says-fda-will-accept-positive-interim-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dendreon will delay Provenge, cuts jobs</title>
		<link>http://www.psa-rising.com/blog/2007/05/dendreon-will-delay-provenge-cuts-jobs/</link>
		<comments>http://www.psa-rising.com/blog/2007/05/dendreon-will-delay-provenge-cuts-jobs/#comments</comments>
		<pubDate>Fri, 18 May 2007 04:48:17 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/05/17/dendreon-will-delay-provenge-cuts-jobs</guid>
		<description><![CDATA[Seattle P-I reporter DAN RICHMAN in an article updated tonight writes:
Seattle-based Dendreon Corp. will delay releasing its much-anticipated Provenge drug to fight prostate cancer until at least next year and possibly until 2010, spokeswomen said Thursday.
Because of that delay, the company Thursday cut 15 percent of its 250-person work force, laying off the roughly 40 [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/05/dendreon-will-delay-provenge-cuts-jobs/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Provenge Profit Taking</title>
		<link>http://www.psa-rising.com/blog/2007/05/provenge-profit-taking/</link>
		<comments>http://www.psa-rising.com/blog/2007/05/provenge-profit-taking/#comments</comments>
		<pubDate>Fri, 11 May 2007 23:01:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Dendreon investors.]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/05/11/provenge-profit-taking</guid>
		<description><![CDATA[Dendreon&#8217;s CEO Mitchell Gold traded some of his stock during the high period following the FDA Advisory panel vote on his company&#8217;s prostate cancer immunotherapy sipuleucal-T (Provenge). Gold told the WSJ Health blog that he sold &#8220;less than 20%&#8221; of his holdings in the company following the upbeat FDA advisory panel vote. &#8220;it&#8217;s all public,&#8221; [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/05/provenge-profit-taking/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
